Your browser doesn't support javascript.
loading
A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety.
Dubcenco, E; Beers-Block, P M; Kim, L P; Schotland, P; Levine, J G; McCloskey, C A; Bashaw, E D.
Affiliation
  • Dubcenco E; Robarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
  • Beers-Block PM; Rutgers, State University of New Jersey, The Biopharma Educational Initiative, Newark, New Jersey, USA.
  • Kim LP; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA.
  • Schotland P; U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Levine JG; Rutgers, State University of New Jersey, The Biopharma Educational Initiative, Newark, New Jersey, USA.
  • McCloskey CA; Rutgers, State University of New Jersey, The Biopharma Educational Initiative, Newark, New Jersey, USA.
  • Bashaw ED; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA.
Clin Transl Sci ; 10(5): 387-394, 2017 Sep.
Article in En | MEDLINE | ID: mdl-28618191
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proton Pump Inhibitors Limits: Humans Language: En Journal: Clin Transl Sci Year: 2017 Document type: Article Affiliation country: Canadá Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proton Pump Inhibitors Limits: Humans Language: En Journal: Clin Transl Sci Year: 2017 Document type: Article Affiliation country: Canadá Country of publication: Estados Unidos